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a b s t r a c t
Oral rotavirus vaccines have consistently proven to be less immunogenic among infants in developing
countries. Discrepancies in the intestinal microbiota, including a greater burden of enteropathogens
and an altered commensal community composition, may contribute to this trend by inhibiting the repli-
cation of vaccine viruses. To test this possibility, we performed a nested case–control study in Vellore,
India, in which we compared the intestinal microbiota of infants who responded serologically or not after
two doses of Rotarix delivered at 6 and 10 weeks of age as part of a clinical trial (CTRI/2012/05/002677).
The prevalence of 40 bacterial, viral, and eukaryotic pathogen targets was assessed in pre-vaccination
stool samples from 325 infants using singleplex real-time PCR on a Taqman array card (TAC). In a subset
of 170 infants, we assessed bacterial microbiota composition by sequencing the 16S rRNA gene V4 region.
Contrary to expectations, responders were more likely than non-responders to harbor 1 bacterial enter-
opathogen at dose 1 (26% [40/156] vs 13% [21/157] of infants with TAC results who completed the study
per protocol; v2, P = .006), although this was not apparent at dose 2 (24% [38/158] vs 23% [36/158]; P =
.790). Rotavirus shedding after dose 1 was negatively correlated with the replication of co-administered
oral poliovirus vaccine (OPV). We observed no consistent differences in composition or diversity of the
16S bacterial microbiota according to serological response, although rotavirus shedding was associated
with slightly more bacterial taxa pre-vaccination. Overall, our findings demonstrate an inhibitory effect
of co-administered OPV on the first dose of Rotarix, consistent with previous studies, but in the context of
OPV co-administration we did not find a strong association between other components of the intestinal
microbiota at the time of vaccination and Rotarix immunogenicity.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Each year, an estimated 215,000 children die of severe gas-
troenteritis associated with rotavirus infection, including between
47,000 and 79,000 in India [1,2]. Although two internationally-
licensed oral rotavirus vaccines, Rotarix (RV1) and RotaTeq, are
currently available, their efficacy is impaired in low-income coun-
tries [3]. Mechanisms responsible for this phenomenon remain
uncertain, but may include maternal antibodies, histo blood group
antigen phenotype, malnutrition, environmental enteropathy, and
interference by enteric infections [4–7]. In a systematic review of
oral poliovirus vaccine (OPV) trials, we observed a reduction in
the odds of seroconversion and vaccine virus shedding among
individuals infected with non-polio enteroviruses (NPEVs) [8].
Similarly, during a recent study in Bangladesh, enterovirus quan-
tity at the time of immunization was negatively correlated with
the immunogenicity of both OPV and RV1 [9].
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The composition of the bacterial microbiota may also shape
response to oral vaccines. Viruses exploit microbiota-derived com-
pounds to replicate efficiently in the intestinal mucosa, as evi-
denced by the reduced pathogenicity of poliovirus and rotavirus
in antibiotic-treated mice [10,11]. Significant geographic variation
occurs in the composition of the infant microbiota [12,13], which
may in turn contribute to discrepancies in vaccine performance.
We carried out a nested case–control study among infants
enrolled in a clinical trial of RV1 immunogenicity in India [14].
Herein, we tested the hypothesis that failure to seroconvert would
be associated with an elevated pathogen burden and an altered
bacterial microbiota composition.
2. Materials and Methods
2.1. Study population
Full details of the study design, laboratory procedures, and sta-
tistical analyses are provided in the Supplementary Methods. Sam-
ples were obtained from a randomized, placebo-controlled trial
assessing the impact of daily supplements of zinc and/or probiotics
(Lactobacillus rhamnosus GG) on the immunogenicity of RV1 and
OPV doses co-administered at 6 and 10 weeks of age [14]. The trial
was performed in Chinnallapuram, a densely populated urban area
in Vellore, India [15]. Infants were considered eligible for enroll-
ment if they were between 35 and 41 days of age, weighed at least
3.2 kg, were available for the duration of the follow-up period, and
had no medical conditions that precluded involvement. Written
informed consent was obtained from parents or guardians prior
to recruitment. Infants received routine vaccines according to the
national schedule in India, including OPV at birth, but were
excluded if they had received any other doses of OPV or rotavirus
vaccine.
Serum anti-rotavirus VP6 IgA antibodies were measured at 6
and 14 weeks of age using an antibody-sandwich enzyme
immunoassay [16]. Rotavirus seroconversion was defined as a
four-fold increase in anti-VP6 IgA concentration or detection of
antibodies at 20 U/ml in previously seronegative infants. Here-
after, we refer to infants who seroconverted to rotavirus as respon-
ders and infants who failed to seroconvert as non-responders.
Following completion of the trial, we conducted a nested case–
control study to assess the association between enteropathogens
and RV1 response. Infants were considered eligible for the study
if they received supplements or placebo, received scheduled doses
of OPV and RV1, and provided paired serum samples. To meet sam-
ple size requirements (Supplementary Methods), we analyzed
stool samples from all responders, subject to constraints in sample
availability (n = 162). We randomly selected an approximately
equal number of non-responders from each study arm (n = 163)
to account for the potential confounding of treatment group with
enteropathogen burden. Baseline characteristics were comparable
between responders and non-responders (Table 1).
In a subset of 170 infants that had been assessed for entero-
pathogen burden (including 85 responders), we sequenced the
16S rRNA gene V4 region in stool samples collected before each
RV1 dose to assess the intestinal bacterial microbiota. For this
microbiota subset we preferentially sampled recipients of
placebo-only and probiotics-only, enabling us to assess the effect
of probiotics on microbiota composition as a secondary objective.
2.2. Enteropathogen testing by TaqMan array card
Stool samples were obtained on the day of or preceding each
vaccine dose. These were kept at room temperature until collection
(which typically occurred within 4 h), transported in cold boxes to
the laboratory, then stored at 70 C until testing, with up to two
intervening freeze–thaw cycles for aliquoting. We extracted DNA
and RNA from 200 mg of the 6- and 10-week pre-vaccination stools
from each infant and assessed the presence of 40 enteropathogen
targets via real-time reverse transcription PCR (RT-PCR) using Taq-
Man array cards (TACs) [17,18]. A threshold cycle (Ct) value of 35
was used as a cut-off for pathogen detection [17]. Enterovirus-
positive samples were assessed for the presence of Sabin polio-
viruses using multiplex RT-PCR [19]. To assess RV1 replication
(or ‘take’), we quantified rotavirus shedding in samples collected
pre-vaccination (indicative of natural rotavirus exposure) and 4
and 7 days after the 6-week dose using a VP6-specific real-time
RT-PCR assay [20,21].
2.3. Characterization of the intestinal microbiota by 16S rRNA gene
sequencing
Our laboratory and bioinformatic pipelines for assessment of
the bacterial microbiota have previously been described [22]. We
amplified the 16S rRNA gene V4 region using primers 515F (50-G
TGCCAGCAGCCGCGGTAA-30) and 806R (50-GGACTACCAGGGTATC
TAAT-30) in DNA extracted from stool samples collected at 6 and
10 weeks of age in each infant. Purified PCR products were
sequenced in two Illumina MiSeq runs (2  151 bp) [23]. Reads
were assembled using FLASH [24] and analyzed using QIIME (Mac-
QIIME version 1.8.0) [25]. After quality filtering [26] and chimera
removal, sequences were clustered de novo into operational taxo-
nomic units (OTUs) with 97% nucleotide identity using uclust
and taxonomically assigned using the RDP classifier [27].
2.4. Statistical analysis
2.4.1. Enteropathogen burden
Analyses were performed on infants who completed the study
per protocol (as defined by Lazarus et al. [14]). Our primary out-
come was the association between rotavirus seroconversion and
the presence of 1 enteropathogen at 6 or 10 weeks of age, as
determined via logistic regression. We excluded enteroaggregative
Escherichia coli (EAEC) from the primary outcome analysis based on
the high prevalence of this target in an interim analysis and its lim-
ited association with diarrhea during previous studies in resource-
poor settings using TACs [28], and enteroviruses given that they
may reflect replication of OPV rather than natural enteropathogen
exposure.
As secondary outcomes, we compared the prevalence of indi-
vidual pathogens, pathogen groups (bacterial, viral, eukaryotic, or
any), mixed infections (defined as >1 enteropathogen), Sabin
viruses, and concurrent diarrhea (defined as 3 loose stools in a
24-h period within the 7 days preceding vaccination) according
to RV1 outcome (seroconversion/shedding) at each dose using
the v2 test or Fisher’s exact test (the latter applied if there were
<5 infected or uninfected individuals in a given comparison). The
presence of an enterovirus in the absence of any Sabin viruses
was defined as an NPEV, though notably our assays did not allow
distinction of samples positive for both Sabin viruses and NPEVs.
For prevalence estimates, 95% confidence intervals (CIs) were cal-
culated using the Clopper–Pearson exact method [29]. Wilcoxon’s
rank sum test was used to compare total pathogen count and Ct
values at each dose according to RV1 outcome; lower Ct values cor-
respond to higher target copy numbers and were used as an indi-
cator of increased pathogen abundance. Rotaviruses were
excluded from analyses of mixed infections, pathogen groups,
and pathogen count given that, in contrast to the hypothesized
inhibitory effect of enteropathogens, one would expect natural
rotavirus exposure or RV1 shedding to be positively correlated
with rotavirus seroconversion. Across the 6- and 10-week doses,
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we assessed the association between the number of doses in which
1 enteropathogen was present (0, 1, or 2) and rotavirus serocon-
version via logistic regression.
Type 3 poliovirus seroconversion rate was compared according
to rotavirus seroconversion status using the v2 test, as was the
prevalence of dose 1 rotavirus shedding. To assess the potential
impact of poliovirus replication following the birth dose of OPV
on the take of OPV administered at 6 weeks, we compared the
shedding of enteroviruses (including Sabin serotypes and NPEVs)
at 10 weeks of age (i.e., 4 weeks after vaccination) according to
whether 1 Sabin serotype was present in the 6-week samples
(also using the v2 test).
P values of .05 were considered significant. For comparisons of
prevalence or abundance for individual TAC targets present in at
least 1% of the study population, P values were adjusted via Ben-
jamini–Hochberg false discovery rate (FDR) correction [30]. All
analyses were carried out in the programming language R [31].
2.4.2. Microbiota composition
After quality filtering, we obtained a minimum of 3726
sequences per sample, which we standardized to 3500 sequences
per sample. For comparisons of within-sample (alpha) diversity,
we evaluated OTU count (overall and within the enteropathogen-
rich phylum Proteobacteria) and Shannon index as continuous
dependent variables via linear regression. Unweighted and
weighted Unifrac distances were used to assess divergence
between samples (beta diversity), and cluster significance deter-
mined using the adonis function in the R package vegan [32]. We
also used Unifrac distances between samples collected from the
same infant over time as a measure of microbiota stability, and
compared this measure between infants using Wilcoxon’s rank
sum test. Differences in relative taxon abundance were assessed
using a non-parametric test based on a bootstrapped t statistic
[33]. We report on any associations with a P value of <.15 after
FDR correction. Random Forest models were fit to discriminate
infants according to RV1 outcome and study arm based on OTU
abundances [34].
2.4.3. Sensitivity analyses
We carried out sensitivity analyses to assess the influence of Ct
threshold, study arm, amplification efficiency of MS2 (the extrinsic
RNA control in the TACs), baseline rotavirus-specific IgA status, and
seroconversion criteria on the comparisons described above.
3. Results
3.1. RV1 immunogenicity
A companion paper describes the primary outcomes of the trial
[14]. Briefly, out of 551 individuals who completed the study per
protocol, 173 (31%) seroconverted to rotavirus, including 54/137
(39%) recipients of zinc and probiotics, 42/136 (31%) probiotics
recipients, 40/143 (28%) zinc recipients, and 37/135 (27%) placebo
recipients. Infants receiving probiotics (arms 1 + 2) or zinc supple-
mentation (arms 1 + 3) did not differ significantly in their rate of
seroconversion compared with placebo recipients (arms 3 + 4 or
2 + 4, respectively). However, a significant increase in seroconver-
sion rate was observed among infants who received both supple-
ments compared with those who received neither (Fisher’s exact
test, P = .040).
3.2. Association between pathogen burden and seroconversion
3.2.1. Primary outcome
We assessed the presence of enteropathogens using TACs in 325
infants (Table 1). Among per-protocol infants (n = 320), we
obtained eligible TAC assays (positive for the extrinsic DNA control
and at least one RNA target) for 6-week samples in 313 infants, 10-
week samples in 316 infants, and 6- and 10-week samples in 309
infants. We observed 1 enteropathogen (excluding EAEC,
Table 1
Baseline characteristics.
Enteropathogen subset Microbiota subset
Responders (n = 162) Non-responders (n = 163) P Responders (n = 85) Non-responders (n = 85) P
Completed the study per protocol 159 (98.1) 161 (98.8) 1.000 85 (100) 84 (98.8) 1.000
Treatment group
Placebo 36 (22.2) 37 (22.7) - 32 (37.6) 31 (36.5) -
Zinc 35 (21.6) 34 (20.9) 0 (0.0) 0 (0.0)
Probiotics 39 (24.1) 39 (23.9) 34 (41.2) 35 (40.0)
Zinc/probiotics 52 (32.1) 53 (32.5) 19 (22.4) 19 (22.4)
Age at enrollment (days) 35.8 (1.8) 35.9 (1.9) 0.577 36.0 (1.8) 36.0 (2.0) 0.933
Female 86 (53.1) 88 (54.0) 0.912 42 (49.4) 46 (54.1) 0.645
Mother’s education
None 11 (6.8) 8 (4.9) 0.901 4 (4.7) 4 (4.7) 0.677
Primary 24 (14.8) 29 (17.8) 10 (11.8) 13 (15.3)
Secondary 86 (53.1) 87 (53.4) 50 (58.8) 42 (49.4)
Higher secondary 25 (15.4) 25 (15.3) 12 (14.1) 18 (21.2)
Degree/diploma 16 (9.9) 14 (8.6) 9 (10.6) 8 (9.4)
House type
Kutcha (temporary materials) 10 (6.2) 9 (5.5) 0.255 7 (8.2) 3 (3.5) 0.240
Mixed 55 (34) 70 (42.9) 28 (32.9) 36 (42.4)
Pucca (permanent materials) 97 (59.9) 84 (51.5) 50 (58.8) 46 (54.1)
Health status
Any breastfeeding at enrollment 162 (100) 162 (99.4) 1.000 85 (100) 85 (100) 1.000
Positive for rotavirus IgA at baseline 42 (25.9) 45 (27.6) 0.802 18 (21.2) 26 (30.6) 0.220
Diarrhea at 6 or 10 weeks 11 (6.8) 12 (7.4) 1.000 5 (5.9) 7 (8.2) 0.766
Stunted at 6 or 10 weeks 37 (22.8) 51 (31.3) 0.105 22 (25.9) 25 (29.4) 0.732
Underweight at 6 or 10 weeks 25 (15.4) 39 (23.9) 0.069 17 (20.0) 15 (17.6) 0.845
Data are mean (standard deviation) or n (%). Responders and non-responders were compared using Wilcoxon’s rank sum test or Fisher’s exact test. Stunting was defined as a
height-for-age Z score of <2 and underweight as a weight-for-age Z score of <2. One non-responder in the microbiota subset was excluded from the final analyses owing to
a clerical error that led to inclusion of the incorrect samples.
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enterovirus, and rotavirus) at either 6 or 10 weeks in 70/154 (45%)
non-responders and 78/155 (50%) responders (odds ratio [OR] 1.22,
95% CI 0.78–1.90).
3.2.2. Secondary outcomes
EAEC and enteroviruses were the predominant TAC targets at 6
and 10 weeks (Fig. 1A and 1B). Their prevalence did not differ sig-
nificantly according to seroconversion status (Supplementary
Table 1), although enterovirus abundance was greater among
responders than non-responders at 6 weeks (Ct, 29.5 ± 4.5 [mean
± standard deviation (SD)] vs 31.0 ± 4.1; Wilcoxon’s rank sum,
FDR-corrected P = .042). The majority of enterovirus-positive sam-
ples (155/217 [71%] and 176/235 [75%] at 6 and 10 weeks, respec-
tively) contained 1 Sabin serotype (Supplementary Fig. 1).
Other enteropathogens were generally more common in RV1
responders than non-responders at 6 weeks (Fig. 1A), although
no individual comparisons of prevalence or abundance were signif-
icant after FDR adjustment (Supplementary Table 1). Combining
across TAC targets, 1 enteropathogen (excluding EAEC, entero-
virus, and rotavirus) was observed in 56/156 (36%) responders
and 37/157 (24%) non-responders at 6 weeks (v2, P = .017). This
discrepancy can be attributed primarily to bacterial pathogens,
which were more common in RV1 responders than non-
responders (40/156 [26%] vs 21/157 [13%] excluding EAEC; v2, P
= .006). These differences were no longer apparent at 10 weeks
(Fig. 1B). The prevalence of viral enteropathogens other than enter-
oviruses and of eukaryotic enteropathogens did not differ signifi-
cantly between responders and non-responders at either dose.
We detected up to six pathogens per sample with an average of
1.6 (SD 1.0) and 1.8 (SD 1.0) at 6 and 10 weeks, respectively. The
prevalence of mixed infections did not differ significantly accord-
ing to seroconversion status at 6 or 10 weeks (v2, P values >.05),
nor did total pathogen count (Wilcoxon’s rank sum, P values
>.05; Fig. 1C and 1D). Concurrent diarrhea was documented in
Fig. 1. Association between concurrent pathogens and seroconversion after two doses of Rotarix. Prevalence of concurrent pathogens at (A) 6 weeks and (B) 10 weeks of age
by seroconversion status. Pathogens present in at least 1% of the study population are included. (C, D) Pathogen count and mixed infection prevalence at (C) 6 weeks and (D)
10 weeks of age by seroconversion status. Mean pathogen counts are indicated by dotted lines. (E) Impact of concurrent enteropathogens at 6 and 10 weeks of age on the odds
of seroconversion. Rotaviruses were excluded from analyses of pathogen groups, mixed infections, and pathogen count. *P < .05. Abbreviations: Bac, bacteria; EAEC,
enteroaggregative Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; EV, enterovirus; Euk, eukaryote; OR, odds ratio; Vir, virus; w, weeks.
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<5% of individuals at 6 and 10 weeks; this proportion did not differ
between responders and non-responders at either dose (v2, P val-
ues >.05).
3.2.1. Pathogen prevalence over successive doses
Compared with infants clear of enteropathogens at both 6 and
10 weeks, we observed a significant increase in the odds of sero-
conversion when 1 pathogen (excluding EAEC, enterovirus, and
rotavirus) was present at both doses (OR 2.25, 95% CI 1.15–4.41;
Fig. 1E) – an effect that was absent among individuals infected at
only one dose (OR 0.91, 95% CI 0.55–1.50). A similar trend was
apparent when considering only bacterial pathogens (OR 1.32,
95% CI 0.76–2.31 and OR 1.98, 95% CI 0.93–4.23 in association with
the presence of 1 bacterial pathogen [excluding EAEC] at one or
both doses, respectively).
3.3. Association between enteropathogen burden and RV1 take
Rotavirus shedding at >100 copies per reaction at 4 and/or 7
days following the first dose of RV1 was observed in 66/278
(24%) per-protocol infants with complete samples and no pre-
vaccination shedding (Supplementary Fig. 2). Among shedders,
46/66 (70%) seroconverted, compared with 95/212 (45%) non-
shedders (v2, P < .001). Baseline characteristics were comparable
between shedders and non-shedders (Supplementary Table 2),
with the exception of rotavirus-specific serum IgA, which was
detected in 8/66 (12%) shedders and 65/212 (31%) non-shedders
(Fisher’s exact test, P = .002). We observed no association between
intestinal bacteria, eukaryotes, mixed infections, concurrent diar-
rhea, or pathogen count at 6 weeks and the prevalence of shedding
(P values >.05; Fig. 2A; Supplementary Table 3). Enterovirus abun-
dance at 6 weeks was significantly greater in shedders than non-
shedders (Ct, 28.8 ± 4.3 vs 30.5 ± 4.3; Wilcoxon’s rank sum, FDR-
corrected P = .046; Supplementary Table 3) – a discrepancy attri-
butable in part to a greater prevalence of Sabin viruses (Fig. 2B).
In addition, shedding of rotavirus appears to be associated with
the diminished replication of co-administered OPV, since entero-
virus prevalence at 10 weeks of age (i.e., 4 weeks later) was lower
in rotavirus shedders than non-shedders (39/65 [60%] vs 166/210
[79%]; v2, P = .014; Fig. 2C) – a trend that was also evident among
Sabin viruses (29/64 [45%] vs 122/209 [58%]; v2, P = .066).
Nonetheless, after two doses rotavirus seroconversion did not dif-
fer by type 3 poliovirus seroconversion status (146/447 [33%] sero-
converted among poliovirus sero-responders and 26/103 [25%]
among non-responders; v2, P = .143). Poliovirus shedding at 10
weeks was significantly lower among individuals shedding polio-
virus at 6 weeks (Fig. 2D).
3.4. Association between bacterial microbiota composition and RV1
outcome
We obtained an average of 25,254 (SD 13,091) sequences per
sample, encompassing 153 OTUs. The composition of the
Fig. 2. Association between concurrent pathogens and Rotarix replication. (A) Prevalence of concurrent pathogens at 6 weeks of age according to shedding status at 4 and/or
7 days after the first dose of RV1. Pathogens present in at least 1% of the study population are included. (B, C) Prevalence of Sabin viruses and NPEVs at 6 and 10 weeks of age
according to shedding status. (D) Prevalence of enteroviruses at 10 weeks of age according to the shedding of  1 Sabin virus at 6 weeks. The shedding of Sabin viruses at 10
weeks of age was used as an indicator of take following the OPV dose administered at 6 weeks. *P < .05; **P < .005. Abbreviations: Bac, bacteria; EAEC, enteroaggregative
Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; Euk, eukaryote; EV, enterovirus; NPEV, non-polio enterovirus; RV, rotavirus; Sabin+, positive for
1 Sabin serotype; Sabin-, negative for all Sabin serotypes; STEC, Shiga toxin-producing E. coli; Vir, virus; w, weeks.
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microbiota was similar at 6 and 10 weeks (Fig. 3A), with a small
number of dominant OTUs (Supplementary Fig. 3).
Analyses of alpha and beta diversity are summarized in Supple-
mentary Table 4. We observed no significant differences in micro-
biota diversity (Fig. 3B), stability (Supplementary Fig. 4), or taxon
relative abundance (non-parametric t test, FDR-corrected P values
>.15; Supplementary Table 5) according to seroconversion status,
and no significant clustering of samples based on Unifrac distances
(adonis, P values >.05; Fig. 3C; Supplementary Fig. 5). Infants who
shed rotavirus 4 and/or 7 days after the 6-week RV1 dose harbored
a greater number of OTUs before vaccination (linear regression, P =
.007; Fig. 3D). We also observed a significant difference in pre-
vaccination microbiota composition according to shedding status
based on unweighted Unifrac (adonis, P = .032; Fig. 3E), but this
accounted for a very small proportion of the variance among sam-
ples (R2 = 0.012). Rotavirus shedding was not associated with
microbiota stability between 6 and 10 weeks (Supplementary
Fig. 4C), nor did we observe any differences in pre-vaccination
taxon abundance between shedders and non-shedders (non-
parametric t test, FDR-corrected P values >.15). At 10 weeks, a
modest enrichment of the phyla Bacteroidetes and Verrucomicro-
bia was observed among infants who shed rotavirus following
the 6-week RV1 dose (Supplementary Table 6).
Random Forest models based on OTU abundance data failed to
accurately predict rotavirus seroconversion (mean accuracy 43.4%
and 45.7% at 6 and 10 weeks, respectively; baseline accuracy,
50.6%; P values >.05), but showed modest predictive accuracy for
shedding after dose 1 (mean accuracy 60.3% and 60.8% based on
OTUs measured at 6 and 10 weeks, respectively; baseline accuracy,
50.0%; P = .038 and .040; Supplementary Fig. 6).
3.5. Impact of probiotics on the bacterial microbiota
Our study was designed to compare microbiota composition
according to seroconversion status, and we therefore included an
equal number of responders and non-responders rather than a ran-
dom sample from each study arm. However, since 16S microbiota
composition was not strongly correlated with seroconversion sta-
tus, we pursued an exploratory analysis of microbiota diversity
and composition by study arm. Overall, the impact of study arm
was modest (Fig. 4), as discussed further in the Supplementary
Results. The probiotic strain appears to correspond to a single
OTU, classified as Lactobacillus zeae, which was more prevalent
and abundant in infants receiving the probiotic intervention
(Fig. 4A). Among probiotic recipients, pre-vaccination abundance
of this OTU was associated with rotavirus shedding after dose 1,
but not seroconversion (Supplementary Fig. 7).
3.6. Sensitivity analyses
Sensitivity analyses are discussed in the Supplementary Results.
4. Discussion
Throughout early life, infants living in resource-poor settings
are exposed to multiple, diverse enteropathogens. The negative
repercussions of repeated pathogen exposure include deficits in
growth [35], gut integrity [36], and OPV immunogenicity [8].
Among infants in south India, we observed a high prevalence of
enteropathogens (albeit generally in the absence of symptoms).
However, we did not observe an inhibitory effect of these
Fig. 3. Association between microbiota composition and Rotarix response. (A) Phylum- and genus-level composition of the bacterial microbiota at 6 and 10 weeks of age. (B)
OTU count and Shannon index (mean ± standard error) by rotavirus seroconversion status. (C) Unweighted Unifrac distances between 6-week samples, visualized via
principal coordinates analysis. (D, E) Equivalent alpha and beta diversity plots are displayed with respect to shedding status after the 6-week RV1 dose. *P < .05.
Abbreviations: OTU, 97%-identity operational taxonomic unit; PC, principal coordinate; RV, rotavirus; RV1, Rotarix; w, weeks.
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enteropathogens on RV1. Indeed, infants harboring 1 bacterial
pathogen during both doses were more likely to respond to this
vaccine.
Rotavirus shedding following the 6-week vaccine dose was pos-
itively associated with rotavirus seroconversion but negatively cor-
related with the take of co-administered OPV. This observation is
consistent with an inhibitory effect of OPV on RV1 (although we
observed no inhibitory association between the immunogenicity
of these vaccines after two doses) [37]. Given their potential to
interfere with OPV [8], the presence of pathogenic bacteria at 6
weeks of age may perhaps have enhanced RV1 immunogenicity
by inhibiting the replication of co-administered Sabin viruses.
Alternatively, concurrent bacteria may have promoted RV1
immunogenicity via an adjuvant effect (e.g., through the induction
of TLR signaling). It is worth noting, however, that the association
between bacterial pathogens and RV1 response was contingent on
the exclusion of EAEC, which we omitted from primary compar-
isons because of its high prevalence and limited association with
diarrhea during previous studies in resource-poor settings using
TACs [28]. Irrespective of whether EAEC was included, our findings
do not support the view that bacterial pathogens impair the
immunogenicity of RV1 – a conclusion consistent with recent find-
ings from Bangladesh [9].
Infantswho shed rotavirus after their 6-weekRV1dose exhibited
a higher prevalence of enteroviruses at the time of vaccination.
These enteroviruses can be attributed primarily to the residual
replication of Sabin viruses administered at birth. Again, this obser-
vationmay relate to the replication of Sabin viruses co-administered
with RV1. The take of OPV given at 6 weeks was diminished among
infants shedding Sabin viruses at that time, potentially reflecting an
inhibitory effect of continued replication of the OPV birth dose or of
vaccine-induced mucosal immunity. By either mechanism, existing
Sabin polioviruses may have enhanced RV1 response by inhibiting
the replication of co-administered OPV (conceptual model in Sup-
plementary Fig. 8). Prior rotavirus exposure, inferred by the pres-
ence of rotavirus-specific serum IgA at baseline, has been linked
Fig. 4. Impact of probiotic supplements on the bacterial microbiota. (A) Receipt of probiotics resulted in enrichment of a single OTU (classified as L. zeae). Mean relative
abundance of this OTU in each study arm is indicated by a horizontal line, while prevalence is indicated by a cross. (B) OTU count and Shannon index (mean ± standard error)
by study arm. (C) Unweighted Unifrac distances between 6-week samples, visualized via principal coordinates analysis. (D) Mean accuracy (±SD) across 100 iterations of the
Random Forest algorithm for models predicting receipt of probiotics-only (upper) or zinc and probiotics (lower). OTU 21300 corresponds to the Lactobacillus strain that was
enriched among probiotics recipients. (E, F) Highest-ranking taxa (and corresponding OTU IDs) by Random Forest importance score (mean decrease in accuracy ± SD) for
models predicting receipt of (E) probiotics-only and (F) zinc and probiotics. *P < .05; **P < .005. Abbreviations: LGG, probiotics (Lactobacillus rhamnosus GG); OTU, 97%-identity
operational taxonomic unit; PC, principal coordinate; w, weeks; Zn, zinc.
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with impaired RV1 immunogenicity in several previous studies
[6,38]. Here, IgA seropositivity at baselinewas negatively correlated
with dose 1 shedding but not with seroconversion after two doses.
We observed no differences in the composition or stability of
the bacterial microbiota according to rotavirus seroconversion sta-
tus. A greater OTU count and shift in overall community structure
was apparent in individuals who shed rotavirus after the first RV1
dose. However, the size of this effect was modest and was not
indicative of dysbiosis. These findings do not necessarily preclude
a role of the intestinal microbiota in shaping broader geographic
trends in RV1 immunogenicity. The composition of the microbiota
among infants in this study is likely to differ considerably from
that of infants in high-income countries [12]. Given the poor sero-
conversion rates observed in this trial (31%), it is possible that all
infants harbored a bacterial community structure inhibitory to
RV1 replication.
Our findings are at odds with a recent study of RV1 in Ghana,
wherein infants who seroconverted exhibited a lower abundance
of Bacteroidetes, a higher abundance of bacteria related to Strepto-
coccus bovis, and a microbiota composition closer to that of Dutch
infants compared with non-seroconverters [39]. The authors of
that paper speculate that bacteria related to S. bovis may be more
immunostimulatory than those in the Bacteroidetes phylum,
potentially acting as an adjuvant to the rotavirus vaccine. However,
we observed no significant differences in microbiota composition
(including Streptococcus abundance) according to RV1 seroconver-
sion and greater abundance of Bacteroidetes at 10 weeks of age
among rotavirus shedders. These discrepancies may reflect differ-
ences in methodology (next-generation sequencing versus
microarray) or baseline microbiota composition, and highlight
the difficulties that are likely to be faced in identifying mechanistic
links between the intestinal microbiota and oral vaccine outcome
using observational data.
The administration of probiotics had a minimal impact on the
intestinal microbiota of these infants, as illustrated by the failure
of Random Forest models to accurately distinguish infants by study
arm when the OTU corresponding to the probiotic strain was omit-
ted. Despite the daily administration of 1010 organisms, the
enriched OTU accounted for a mean relative abundance of <1%
among probiotic recipients at 6 and 10 weeks, potentially reflect-
ing passive transit rather than successful colonization.
Our study was limited by the lack of shedding data for the sec-
ond RV1 dose. Although demography, growth, and several other
baseline characteristics did not differ between the responders
and non-responders included in this study, we did not consider
several other potential confounders that may influence microbiota
composition in early infancy, such as mode of delivery and antibi-
otic exposure [22,40]. Factors such as primer selection and sample
handling (e.g., freeze–thaw cycles) may have introduced bias into
our assessment of microbiota composition [41,42]. However, these
were present across all samples and would therefore have influ-
enced comparison groups equally. Finally, co-administration of
OPV may have obscured a role for other enteric viruses, particu-
larly NPEVs, in shaping RV1 immunogenicity. Further study among
infants receiving inactivated poliovirus vaccine rather than OPV
would allow the significance of NPEVs for RV1 immunogenicity
to be tested.
Overall, our findings support a modest inhibitory effect of co-
administered OPV on the first dose of RV1. However, we did not
observe a greater pathogen burden among infants who failed to
respond to RV1, nor did we observe any major differences in bac-
terial microbiota composition in these individuals. Future studies
on a broader geographic and socioeconomic scale, or those consid-
ering different aspects of microbial community composition or
function, may yet reveal an important role for the intestinal micro-
biota in shaping RV1 response.
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